Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax With or Without Cyclophosphamide or Pembrolizumab in CLL
NCT03219450Phase 1Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2021
- Primary completion
- Jul 2027
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NeoVax in chronic lymphocytic leukemia (CLL) (3 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Feasibility of neoantigen identification at 6 months, Feasibility of vaccine generation at 6 months and 1 more. Started Aug 2021; status: recruiting.
02
Drugs
NeoVax
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03219450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03219450.